ArticleAdvances in radiation oncology2026
Establishing a Clinically Relevant Radiation Therapy Method for Preclinical Medulloblastoma Research.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Craniospinal irradiation (CSI) is a cornerstone of pediatric brain cancer therapy, yet detailed, reproducible protocols for accurate CSI delivery in preclinical mouse models remain scarce, hindering translational research and the development of radiosensitizing strategies. We aimed to establish a clinically relevant, easily replicable radiation therapy protocol for medulloblastoma (MB) mouse models, providing a robust platform for preclinical evaluation of novel therapeutic combinations. We hypothesized that multifraction CSI would most closely mirror clinical practice and achieve clinically representative disease control. Methods and Materials: Four radiation therapy strategies were compared to optimize treatment of orthotopic MB xenografts in mice: highly focal irradiation, regional brain targeting, whole brain exposure, and CSI. Mice received fractionated X-ray treatment using an X-RAD SmART 225Cx system. Survival was assessed by Kaplan-Meier analysis, recurrence patterns by histology, and DNA damage response activation by immunohistochemistry. Results: We evaluated 7 commonly used MB models (D283, D425, SU-MB002, MED813FH, MED211FH, TK-MB913, and a murine allograft). Focal irradiation provided minimal disease control, whereas regional brain targeting extended survival but failed to prevent rapid regrowth. Whole brain irradiation delayed progression but allowed spinal metastases. In contrast, multifraction CSI significantly improved survival across all models, with recurrence localized to the implantation site. Immunohistochemistry confirmed activation of DNA damage response pathways and cell cycle arrest, with distinct patterns between Conclusions: Multifraction CSI most accurately replicates clinical treatment and relapse patterns, outperforming focal and whole brain approaches. By defining CSI as the optimal strategy, we provide a clinically aligned, reproducible protocol with optimized dosing for common MB models, that will accelerate translational research and drive the development of next-generation radiosensitizers for pediatric brain tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.